Brief: Baudax Bio Says Received Deficiency Letter From Staff Of Nasdaq
08/07/2022 21:21
July 8 (Reuters) - Baudax Bio Inc BXRX.O :
* BAUDAX BIO- ON JULY 6 RECEIVED DEFICIENCY LETTER FROM
STAFF OF
NASDAQ
* BAUDAX BIO- INTENDS TO ACTIVELY MONITOR CLOSING BID PRICE
FOR
COMMON STOCK, CONSIDER AVAILABLE OPTIONS TO RESOLVE DEFICIENCY,
REGAIN COMPLIANCE WITH RULE 5550(A)(2)
Source: (https://bit.ly/3Rj4pwW)
Further company coverage: BXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer